Clopidogrel Bisulfate biggerst supplier CAS NO.120202-66-6

1 We are a business group listed on the Chinese Stock Market with more than 20 years of experience providing customized services.

2.A broad range of high quality products, manufactured by leading producers, and supported with outstanding quality control systems.

3.Professional and outstanding logistic expertise.

4. Proven state of the art service and reliability.

5.Highly skilled scientific and technical staff, assuming product and market development, and guaranteeing optimal support to customers and suppliers on promotion, registration, marketing and sales.

6.Competence for product and concept development.

TIANMA established in 1993 in Suzhou China, we are the leading manufacturers of:

• Advanced Intermediates
• APIs
• Nutritions
• Peptide Related Chemicals
• Phosgene & NaCN Derivatives
• Specialty Chemicals synthetic

In order to offer the best Contract Manufacture Service to customers, TIANMA sets up one R&D Center and seven production sites around China. The main business of TIANMA not only contains pharmaceutical and chemical, but also expand to nutrition, real estate and hotel chain.

Clopidogrel is an inhibitor of platelet aggregation; doses of 75 mg per day inhibit platelet aggregation by 40 to 60% at steady state, which occurs within 3 to 7 days.

Clopidogrel inhibits adenosine diphosphate (ADP) binding to its platelet receptor and subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thus inhibiting platelet aggregation. Because clopidogrel irreversibly modifies the ADP receptor, platelets are affected for the remainder of their lifespan. An active metabolite, not yet isolated, is responsible for the medication's activity. Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP. Clopidogrel does not inhibit phosphodiesterase activity.